What will be different when a brain implant ceases to be an experimental creation, and begins to resemble a commercial product? Neuralink has been reimagining that query and Elon Musk has been pushing it back into the limelight, terming a very close-term transition of Neuralink out of cautious clinical work and into scale. In a post and a video on X, Musk wrote that Neuralink will proceed to high-volume production and a streamlined, virtually fully automated surgical process in 2026, and he also said: Device threads will pass through the dura, this time they do not have to remove it. This is a big deal.
The title statement associated with that production drive is even greater. At this stage, Musk wrote that he believed the company could restore a fully functional body with Neuralink, the interface of the motor-cortex company. Simply speaking, the promise is a bypass: collect intent on cortex, map it into commands and send the commands to the devices that can act on the world. Musk also claimed that anything that can be operated by a computer or phone can be operated by a Neuralink implant, which is an unrealistic claim that reduces dozens of hard problems such as signal stability, decoding, latency, safety, user training, and regulatory proof into one consumer-like capability.
The current hardware pitch of Neuralink is abnormally clear on an implantable neural interface. The company refers to its N1 implant as an intracortical with 1,024 electrodes distributed over 64 flexible “threads”, including a surgical robot that is designed to insert the threads in a consistent manner. The significance of that architecture is that scaling is not only a business milestone but it is also a quality-control problem in wet biology. A successful implant is subject to a breakthrough. A process must be involved in an implant that is working thousands of times.
In academia, where incentives are biased towards being able to do something instead of being production ready, the discipline has taken years of sitting in one place just to compile the safety record to support chronic implantation. In one example, BrainGate consortium, it was reported that during 12,203 implant-days in 14 participants, there were no occurrences of device-related events, which necessitated an explantation procedure and no intracranial infections associated with the investigational device- published as part of the Braingate feasibility study. This type of longitudinal evidence does not directly support the device developed by Neuralink itself, but it explains what it means to be “credible” with implanted brain-computer interfaces: not just one demo, but years of observation, counting the number of adverse events, experience of explantation, and comparison of this device to other implanted neurologic devices.
Neuralink has also cited increasing human experience with one of its own systems. By September 2025, the company reported having implanted devices in 12 patients, and Musk has demonstrated preliminary user operations, including cursor controlling and software interaction. The parallel labors at the sector makes it clear that there is no correct way in the brain. Another potential solution of accessing the brain through electrodes inserted through blood vessels instead of through open brain surgery was tested in the Stentrode SWITCH study, which represents a more general engineering motif: various access routes have contrasting invasiveness, signal fidelity, and long-term maintenance.
The automation conversation of 2026 highlights a less obvious issue, the bottleneck being the operation rather than the chip. The thread-like electrodes are designed to be thin and flexible and this aspect can minimize tissue strain, but makes manual placement unfeasible at scale. The focus of Neuralink on the robotic workflow and a simplified attitude to the dura indicates the effort to transform neurosurgery to a more industrialized procedure. As soon as a package consisting of a robot and an implant is the product, reliability must be quantified not only by the quality of the neural signals but also by the time taken to get the new equipment ready, the failure modes, and the burden that the training of the new equipment poses to hospitals.
In a second front, Neuralink has established in its roadmap the restoration of vision via Blindsight, a proposed implanting visual cortex. Musk stated that Blindsight was given the FDA designation of breakthrough device and asserted that it was capable of giving users sight even individuals who have lost their eyes or optic nerves, assuming the visual cortex was not damaged. Early quality he also warned about: To set expectations, the vision shall initially be low resolution, like Atari graphics… He then proceeded to outline more speculative abilities, such as infrared or ultraviolet-sightedness.
The name “Atari graphics” makes a connection because it is consistent with what decades of cortical-vision studies have found out again and again: visual prostheses can provide valuable sensations, but that the gap between dots of light and working vision is biologically limited, and the brain itself encodes this information. Cortical visual Prosthesis System Reviews outline various approaches to the device and reiterate that there exist intractable limitations -resolution, long-term biocompatibility, and the transformation of stimulation patterns into coherent perception, but state that a number of systems have entered preclinical trials. The reality of core engineering is that a camera feed is simple; it is difficult to write to neural tissue how the brain can read it in a consistent way as time goes on.
Below two Neuralink flagship ambitions movement and vision, is a more fundamental and far more impactful change: implantable BCIs are beginning to act as a platform industry. Financing and valuation indicators drive the point home; The $650 million Series E raise by Neuralink in 2025 at an estimated valuation of about 9 billion puts the firm less like a lab and more like a manufacturer-in-waiting. Once the automation of production and procedures is really on time, the center-of-mass will no longer be in the question of Can it be done? But rather Who can get it, maintain it and benefit in a way not at risk of introducing unsafe issues?
To readers of Modern Engineering Marvels, the spectacle of a single promise is not the most practical prism through which to view the world, but the coming of age of an interface stack: surgical robots, implantable devices, wireless power and telemetry, decoding software, and operating rooms. The framing of Neuralink and its presentation as an all-body application, mass production, and automated surgery, places strain on all levels simultaneously. The second wave of brain-computer interfaces will never be dominated by a single showcase and rather by the mundane efforts of repeatability.
